Skip to main content
NCBI home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1981 Nov 14;283(6302):1320–1322. doi: 10.1136/bmj.283.6302.1320

The six disease of WHO.

M F Waters
PMCID: PMC1507675  PMID: 6794841

Full text

PDF
1320

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Feldman R. A., Sturdivant M. Leprosy in the United States, 1950-1969: an epidemiologic review. South Med J. 1976 Aug;69(8):970–979. doi: 10.1097/00007611-197608000-00006. [DOI] [PubMed] [Google Scholar]
  2. Godal T., Myklestad B., Samuel D. R., Myrvang B. Characterization of the cellular immune defect in lepromatous leprosy: a specific lack of circulating Mycobacterium leprae-reactive lymphocytes. Clin Exp Immunol. 1971 Dec;9(6):821–831. [PMC free article] [PubMed] [Google Scholar]
  3. Jacobson R. R., Hastings R. C. Rifampin-resistant leprosy. Lancet. 1976 Dec 11;2(7998):1304–1305. doi: 10.1016/s0140-6736(76)92071-7. [DOI] [PubMed] [Google Scholar]
  4. Kirchheimer W. F., Storrs E. E. Attempts to establish the armadillo (Dasypus novemcinctus Linn.) as a model for the study of leprosy. I. Report of lepromatoid leprosy in an experimentally infected armadillo. Int J Lepr Other Mycobact Dis. 1971 Jul-Sep;39(3):693–702. [PubMed] [Google Scholar]
  5. Levy L., Shepard C. C., Fasal P. Clofazimine therapy of lepromatous leprosy caused by dapsone-resistant mycobacterium leprae. Am J Trop Med Hyg. 1972 May;21(3):315–321. doi: 10.4269/ajtmh.1972.21.315. [DOI] [PubMed] [Google Scholar]
  6. PETTIT J. H., REES R. J. SULPHONE RESISTANCE IN LEPROSY. AN EXPERIMENTAL AND CLINICAL STUDY. Lancet. 1964 Sep 26;2(7361):673–674. doi: 10.1016/s0140-6736(64)92482-1. [DOI] [PubMed] [Google Scholar]
  7. Pearson J. M., Haile G. S., Barnetson R. S., Rees R. J. Dapsone-resistant leprosy in Ethiopia. Lepr Rev. 1979 Sep;50(3):183–199. doi: 10.5935/0305-7518.19790024. [DOI] [PubMed] [Google Scholar]
  8. Pearson J. M., Rees R. J., Waters M. F. Sulphone resistance in leprosy. A review of one hundred proven clinical cases. Lancet. 1975 Jul 12;2(7924):69–72. doi: 10.1016/s0140-6736(75)90508-5. [DOI] [PubMed] [Google Scholar]
  9. RIDLEY D. S., JOPLING W. H. A classification of leprosy for research purposes. Lepr Rev. 1962 Apr;33:119–128. doi: 10.5935/0305-7518.19620014. [DOI] [PubMed] [Google Scholar]
  10. Rees R. J., Pearson J. M., Waters M. F. Experimental and clinical studies on rifampicin in treatment of leprosy. Br Med J. 1970 Jan 10;1(5688):89–92. doi: 10.1136/bmj.1.5688.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rees R. J., Waters M. F., Pearson J. M., Helmy H. S., Laing A. B. Long-term treatment of dapsone-resistant leprosy with rifampicin: clinical and bacteriological studies. Int J Lepr Other Mycobact Dis. 1976 Jan-Jun;44(1-2):159–169. [PubMed] [Google Scholar]
  12. Rees R. J., Waters M. F., Weddell A. G., Palmer E. Experimental lepromatous leprosy. Nature. 1967 Aug 5;215(5101):599–602. doi: 10.1038/215599a0. [DOI] [PubMed] [Google Scholar]
  13. Ridley D. S., Jopling W. H. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966 Jul-Sep;34(3):255–273. [PubMed] [Google Scholar]
  14. SHEPARD C. C. Acid-fast bacilli in nasal excretions in leprosy, and results of inoculation of mice. Am J Hyg. 1960 Mar;71:147–157. doi: 10.1093/oxfordjournals.aje.a120098. [DOI] [PubMed] [Google Scholar]
  15. Shepard C. C., Levy L., Fasal P. Rapid bactericidal effect of rifampin on Mycobacterium leprae. Am J Trop Med Hyg. 1972 Jul;21(4):446–449. doi: 10.4269/ajtmh.1972.21.446. [DOI] [PubMed] [Google Scholar]
  16. Shepard C. C., Levy L., Fasal P. The death of Mycobacterium leprae during treatment with 4,4'-diaminodiphenylsulfone (DDS). Initial rate in patients. Am J Trop Med Hyg. 1968 Sep;17(5):769–775. doi: 10.4269/ajtmh.1968.17.769. [DOI] [PubMed] [Google Scholar]
  17. Waters M. F., Rees R. J., McDougall A. C., Weddell A. G. Ten years of dapsone in lepromatous leprosy: clinical, bacteriological and histological assessment and the finding of viable leprosy bacilli. Lepr Rev. 1974 Dec;45(4):288–298. doi: 10.5935/0305-7518.19740034. [DOI] [PubMed] [Google Scholar]
  18. Waters M. F., Rees R. J., Pearson J. M., Laing A. B., Helmy H. S., Gelber R. H. Rifampicin for lepromatous leprosy: nine years' experience. Br Med J. 1978 Jan 21;1(6106):133–136. doi: 10.1136/bmj.1.6106.133. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES